stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Net income
Insmed, Inc.'s net income for fiscal 2025 was −$1.3B, compared with −$913.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$605.6M. Over the past ten years it has ranged from −$1.3B (fiscal 2025) to −$118.2M (fiscal 2015) — the current reading is the lowest in ten years. Net income has fallen for 6 consecutive fiscal years. Insmed, Inc. ranks 594th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$1.3B | — |
| FY2024 | −$913.8M | — |
| FY2023 | −$749.6M | — |
| FY2022 | −$481.5M | — |
| FY2021 | −$434.7M | — |
| FY2020 | −$294.1M | — |
| FY2019 | −$254.3M | — |
| FY2018 | −$324.3M | — |
| FY2017 | −$192.6M | — |
| FY2016 | −$176.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$100.3M | — |
| Jun 2026 | −$13.2M | — |
| Mar 2026 | −$163.6M | — |
| Dec 2025 | −$328.5M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $2.6B |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| INSM Insmed, Inc. | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on INSM
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement